Drug Profile
V 503
Alternative Names: 9-valent HPV vaccine - Merck and Co; 9-valent human papillomavirus vaccine - Merck and Co; 9vHPV vaccine - Merck; GARDASIL; GARDASIL9; Human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52, 58) L1 virus-like particle vaccine - Merck; Human Papillomavirus 9-valent vaccine, Recombinant; Human papillomavirus vaccine recombinant 9-valent - Merck; Human papillomavirus vaccine recombinant nonavalent - Merck; Human papillomavirus vaccine-Merck-9 valent; Multivalent human papillomavirus (HPV) L1 virus-like particle (VLP) vaccine - Merck; Nonavalent HPV VLP Vaccine; Recombinant HPV 9-valent Vaccine; Recombinant HPV Nonavalent Vaccine; Recombinant Human Papillomavirus 9-valent Vaccine; SILGARD9; V-503Latest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Banyu; Merck & Co; Takeda
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Anal cancer; Cervical cancer; Condylomata acuminata; Head and neck cancer; Human papillomavirus infections; Oropharyngeal cancer; Vulvovaginal cancer
- Phase III COVID 2019 infections; Dengue
Most Recent Events
- 13 Mar 2024 Merck AG plans a phase I trial for Human Papillomavirus infections in males (In adolescents, In adults, Prevention) (IM) in the fourth quarter of 2024
- 13 Mar 2024 Merck AG plans a phase I trial for Human Papillomavirus infections in females (In adolescents, In adults, Prevention) (IM) in the fourth quarter of 2024
- 12 Dec 2023 Merck Sharp & Dohme completes a phase III clinical trial in COVID-2019 infections (Prevention, In children) in USA (IM) (NCT05119855) (EudraCT2021-003591-13)